JENNA KOPP: Open Payments
NPI 1851023345 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$89,954 in 217 payments from 17 companies in 2025. Trend: 2023 $10,647 · 2024 $39,053 · 2025 $89,954
Speaker / faculty: $64,722Travel & lodging: $17,851Food & beverage: $3,931Consulting: $3,450
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 64 | $45,718 |
| ABBVIE INC. | 61 | $23,032 |
| Lilly USA, LLC | 37 | $20,259 |
| Gilead Sciences, Inc. | 10 | $181 |
| Madrigal Pharmaceuticals | 8 | $139 |
| GENZYME CORPORATION | 6 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $136 |
| Amgen Inc. | 6 | $115 |
| Intercept Pharmaceuticals, Inc. | 3 | $53 |
| Phathom Pharmaceuticals, Inc. | 5 | $36 |
Products named: TREMFYA, OMVOH, SKYRIZI, RINVOQ, STELARA, DUPIXENT, REZDIFFRA, UPLIZNA.
Industry payments across NE — which companies pay providers there.
